Co-crystal structure guided array synthesis of PPARγ inverse agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 14, 2007, Pages 3916-3920

  Trump, Ryan P ^a   Cobb, Jeffrey E ^a   Shearer, Barry G ^a   Lambert, Millard H ^a   Nolte, Robert T ^a   Willson, Timothy M ^a   Buckholz, Richard G ^a   Zhao, Sumin M ^a   Leesnitzer, Lisa M ^a   Iannone, Marie A ^a   Pearce, Kenneth H ^a   Billin, Andrew N ^a   Hoekstra, William J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Inverse agonist; PPAR

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CARBOXYLIC ACID; FARGLITAZAR; GLUCOSE; GSK 5737; GSK 5775; GW 0072; LIPID; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; LIGAND BINDING; LIPID BLOOD LEVEL; NONHUMAN;

CRYSTALLIZATION; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; OXAZOLES; PPAR GAMMA; TYROSINE;

ANIMALIA;

EID: 34250313113     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.111     Document Type: Article

References (21)

1. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. J. Med. Chem. 43 (2000) 527
2. Shearer B.G., and Hoekstra W.J. Curr. Med. Chem. 10 (2003) 267
3. Tontonoz P., Hu E., and Spiegelman B.M. Cell 79 (1994) 1147
4. Lowell B.B. Cell 99 (1999) 239
5. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien C.R., Koder A., and Evans R.M. Mol. Cell 4 (1999) 585
6. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., and Mortensen R.M. Mol. Cell 4 (1999) 611
7. Nakano R., Kurosaki E., Yoshida S., Yokono M., Shimaya A., Maruyama T., and Shibasaki M. Biochem. Pharm. 72 (2006) 42
8. Jones J.R., Barrick C., Kim K.-A., Lindner J., Blondeau B., Fujimoto Y., Shiota M., Kesterson R.A., Kahn B.B., and Magnuson M.A. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6207
9. Oberfield J., Collins J.L., Holmes C.P., and Goreham D.M. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6102
10. Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., Oplinger J., Kliewer S.A., Gampe R.T., McKee D.D., and Willson T.M. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13919
11. Buckholz, R. G.; Trump, R. P.; Zhao, S.; Iannone, M. A.; Leesnitzer, L. M.; Merrihew, R. V.; Lobe, D. C.; Winegar, D. A.; Lazar, M. A.; Cobb, J. E.; Willson, T. M.; Hoekstra, W. J.; Billin, A. B. Biochem. Biophys. Res. Commun., submitted for publication; also see supplemental material.
12. Xu H.E., Stanley T.B., Montana V.G., and Lambert M.H. Nature 415 (2002) 813
13. Iannone M.A., Simmons C.A., Kadwell S.H., Svoboda D.L., Vanderwall D.E., Deng S.J., Consler T.G., Shearin J., Gray J.G., and Pearce K.H. Mol. Endocrinol. 18 (2004) 1064
14. Co-crystals of compound 2t with the PPARγ LBD were grown from a complex containing 15 mg/ml protein (20 mM Tris, pH 8.0, 5 mM DTT, 100 mM NaCl, 2 mM EDTA) complexed at a 5:1 molar ratio with the compound (at 50 mM in DMSO) using the vapor phase diffusion method. The two co-crystals' PDB codes are 2pob (2t) and 1fm9 (farglitazar).
15. Henke B.R., Blanchard S.G., Brackeen M.F., and Brown K.K. J. Med. Chem. 41 (1998) 5020
16. 3, 300 MHz) δ 8.1 (d, J = 6.1, 2H), 7.5 (m, 2H), 7.4 (m, 6H), 7.3 (m, 1H), 7.2 (s, 3H), 7.0 (m, 2H), 6.8 (d, J = 8.6, 1H), 6.7 (d, J = 8.6, 2H), 4.2 (t, J = 6.1, 2H), 3.0 (d, J = 5.8, 2H), 2.8 (m, 1H), 2.4 (s, 3H), 2.0 (s, 1H), 1.9 (s, 3H), 1.8 (m, 2H), 1.2 (m, 1H). MS (APCI) m/z 574 (M+1).
17. For more information on these genes, see. Way J.M., Harrington W.W., Brown K.K., Gottschalk W.K., Sundseth S.S., Mansfield T.A., Ramachandran R.K., Willson T.M., and Kliewer S.A. Endocrinology 142 (2001) 1269
18. 11 Because only array members shown in Table 2 were run in this assay, results for other high MW array members with an arene/two-carbon tether motif are not available.
19. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., Nakamura M., Miao S., Cao P., Learned R.M., Chen J.-L., and Li Y. J. Biol. Chem. 277 (2002) 19649
20. Camp H.S., Chaudhry A., and Leff T. Endocrinology 142 (2001) 3207
21. The study of a PPARγ inverse agonist in a diabetic animal model will be disclosed in a future communication.